You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

pembrolizumab

( PEM broe LIZ ue mab )
Funding:
New Drug Funding Program
  • Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and Prior Ipilimumab
  • Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and No Prior Ipilimumab
  • Pembrolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer (Second or Subsequent Line)
  • Pembrolizumab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  • Pembrolizumab – Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
  • Pembrolizumab - In Combination with Platinum and Pemetrexed for First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  • Pembrolizumab - In Combination with Carboplatin and Paclitaxel for First-Line Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Other Name(s): Keytruda
Appearance: solution mixed into larger bags of fluids

Patient Info Sheet

Oct 2019

What it is used for

  • For treating certain types of cancers such as skin cancer (called melanoma), lung cancer (called non-small cell) or bladder and urinary tract cancer that has spread or cannot be removed by surgery. It is also used to treat certain patients with Hodgkin lymphoma and a certain type of B-cell lymphoma.
  • Pembrolizumab is an immune therapy drug. For more information on immune therapy, click here.


You might also be interested in